An outpatient, dose-intense, intravenous cisplatin and oral etoposide regimen for the treatment of advanced, platinum-resistant ovarian cancer.
Morgan, Robert David Clamp, Andrew R Hasan, Jurjees Mitchell, Claire L Saunders, Geoff Mescallado, Nerissa Welch, Richard Jayson, Gordon C
Morgan, Robert David
Clamp, Andrew R
Hasan, Jurjees
Mitchell, Claire L
Saunders, Geoff
Mescallado, Nerissa
Welch, Richard
Jayson, Gordon C
Citations
Altmetric:
Abstract
Advanced-stage, platinum-resistant, ovarian cancer can be treated with dose-intense chemotherapy; one such regimen includes intravenous cisplatin and oral etoposide. To minimize the toxicity associated with weekly cisplatin, pretreatment and posttreatment hydration is required, often necessitating inpatient, overnight admission. We report a shorter, within-day regimen for delivering weekly cisplatin.
Authors
Morgan, Robert David
Clamp, Andrew R
Hasan, Jurjees
Mitchell, Claire L
Saunders, Geoff
Mescallado, Nerissa
Welch, Richard
Jayson, Gordon C
Clamp, Andrew R
Hasan, Jurjees
Mitchell, Claire L
Saunders, Geoff
Mescallado, Nerissa
Welch, Richard
Jayson, Gordon C
Description
Date
2018-03
Publisher
Collections
Keywords
Type
Article
Citation
An outpatient, dose-intense, intravenous cisplatin and oral etoposide regimen for the treatment of advanced, platinum-resistant ovarian cancer. 2018, 28(3): 448-452 Int J Gynecol Cancer